What is the share price of Vimta Labs Ltd (VIMTALABS) today?
The share price of VIMTALABS as on 16th May 2025 is ₹1037.95. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Vimta Labs Ltd (VIMTALABS) share?
The past returns of Vimta Labs Ltd (VIMTALABS) share are- Past 1 week: 12.83%
- Past 1 month: 6.36%
- Past 3 months: -7.22%
- Past 6 months: 32.96%
- Past 1 year: 107.22%
- Past 3 years: 201.77%
- Past 5 years: 1429.77%
What are the peers or stocks similar to Vimta Labs Ltd (VIMTALABS)?
The peers or stocks similar to Vimta Labs Ltd (VIMTALABS) include:What is the dividend yield % of Vimta Labs Ltd (VIMTALABS) share?
The current dividend yield of Vimta Labs Ltd (VIMTALABS) is 0.19.What is the market cap of Vimta Labs Ltd (VIMTALABS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Vimta Labs Ltd (VIMTALABS) is ₹2307.83 Cr as of 16th May 2025.What is the 52 week high and low of Vimta Labs Ltd (VIMTALABS) share?
The 52-week high of Vimta Labs Ltd (VIMTALABS) is ₹1178 and the 52-week low is ₹420.What is the PE and PB ratio of Vimta Labs Ltd (VIMTALABS) stock?
The P/E (price-to-earnings) ratio of Vimta Labs Ltd (VIMTALABS) is 34.27. The P/B (price-to-book) ratio is 7.22.Which sector does Vimta Labs Ltd (VIMTALABS) belong to?
Vimta Labs Ltd (VIMTALABS) belongs to the Health Care sector & Labs & Life Sciences Services sub-sector.How to buy Vimta Labs Ltd (VIMTALABS) shares?
You can directly buy Vimta Labs Ltd (VIMTALABS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Vimta Labs Ltd
VIMTALABS Share Price
1,037.953.17% (-33.95)
VIMTALABS Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
VIMTALABS Stock Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
VIMTALABS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 34.95 | 7.22 | 0.19% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 45.21 | 6.44 | 0.55% |
VIMTALABS Analyst Ratings & Forecast
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
VIMTALABS Company Profile
Vimta Labs Limited is engaged in providing testing and contract research services in the fields of clinical and pre-clinical studies, clinical reference, analytical testing, advanced molecular biology and environmental studies.
Investor Presentation
View olderVIMTALABS Similar Stocks (Peers)
Compare with peersDIVISLAB
PE Ratio
76.08
1Y Return
59.74%
Buy Reco %
45.83
SYNGENE
PE Ratio
52.26
1Y Return
6.01%
Buy Reco %
75.00
AARTIPHARM
PE Ratio
26.50
1Y Return
31.08%
Buy Reco %
—
PE Ratio
-21.90
1Y Return
8.30%
Buy Reco %
—
BROOKS
PE Ratio
-20.71
1Y Return
44.06%
Buy Reco %
—
VIMTALABS Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
VIMTALABS Stock Summary · November 2024
Vimta Labs demonstrated robust financial performance in the first half of FY '25, achieving a year-on-year growth of 26.4% driven by its pharmaceutical services, which now account for approximately 70% of revenue. Despite facing inflationary pressures and operational challenges from transitioning to new facilities, the company remains optimistic about future growth, particularly in clinical trials and complex generics. The divestment of its diagnostics business is expected to enhance focus and resource optimization, while ongoing capacity expansions aim to support a targeted quarterly run rate of INR 500 crores by FY '26. Management is cautiously optimistic about maintaining EBITDA margins around 35%, even as they navigate the evolving market dynamics and strategic shifts in service offerings.
Key Points on Vimtalabs Stock
VIMTALABS Stock Growth Drivers
8Strong Financial Performance
Vimta Labs reported significant financial growth, with total income reaching INR 854 million in Q2
Successful Divestment and Focus on Core Services
The divestment of the diagnostics services business to Thyrocare Technologies Ltd. has allowed Vimta Labs
VIMTALABS Stock Challenges
3Operational Challenges in Food Segment
The food segment is currently facing significant operational challenges due to internal transitions, specifically the
Short-term Revenue Risks
The ongoing transitions within the food segment pose a risk of short-term business loss, as
VIMTALABS Forecasts
Price
Revenue
Earnings
VIMTALABS Share Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeVIMTALABS Company Revenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeVIMTALABS Stock EPS (Earnings Per Share) Forecast
Hmm, looks like data is unavailable here. Please come back after some timeVIMTALABS
Income
Balance Sheet
Cash Flow
Annual Normal View
VIMTALABS Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 154.79 | 184.65 | 214.57 | 183.73 | 211.51 | 279.73 | 321.63 | 322.27 | 348.81 | 349.05 | ||||||||||
Raw Materials | 126.54 | 138.18 | 155.10 | 32.41 | 35.25 | 54.81 | 44.13 | 48.69 | 222.03 | 224.15 | ||||||||||
| Power & Fuel Cost | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||||||
| Employee Cost | 57.63 | 57.80 | 71.42 | 86.32 | 95.30 | |||||||||||||||
| Selling & Administrative Expenses | 26.50 | 21.73 | 28.56 | 43.23 | 38.83 | |||||||||||||||
| Operating & Other expenses | 34.22 | 42.94 | 44.43 | 49.60 | 48.65 | |||||||||||||||
EBITDA | 28.25 | 46.47 | 59.47 | 32.97 | 53.79 | 80.51 | 98.35 | 90.80 | 126.78 | 124.90 | ||||||||||
| Depreciation/Amortization | 9.63 | 15.70 | 19.72 | 20.93 | 23.08 | 23.33 | 30.71 | 34.20 | 35.29 | 35.16 | ||||||||||
| PBIT | 18.62 | 30.77 | 39.75 | 12.04 | 30.71 | 57.18 | 67.64 | 56.60 | 91.49 | 89.74 | ||||||||||
| Interest & Other Items | 2.09 | 5.20 | 4.61 | 3.77 | 2.17 | 1.50 | 2.65 | 2.12 | 1.90 | 1.90 | ||||||||||
| PBT | 16.53 | 25.57 | 35.14 | 8.27 | 28.54 | 55.68 | 64.99 | 54.48 | 89.59 | 87.84 | ||||||||||
| Taxes & Other Items | 5.94 | 9.13 | 9.83 | 1.42 | 7.14 | 14.36 | 16.83 | 13.47 | 22.25 | 21.80 | ||||||||||
| Net Income | 10.59 | 16.44 | 25.31 | 6.85 | 21.40 | 41.32 | 48.16 | 41.01 | 67.34 | 66.04 | ||||||||||
| EPS | 4.79 | 7.43 | 11.45 | 3.10 | 9.68 | 18.69 | 21.77 | 18.51 | 30.28 | 29.79 | ||||||||||
| DPS | — | — | — | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.21 | 0.11 | 0.09 | 0.11 | 0.07 | 0.07 |
VIMTALABS Company Updates
FY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2022
Annual report
PDFVIMTALABS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareLabs & Life Sciences Services
Compare valuation on Screener
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Vimta Labs Ltd | 34.27 | 7.22 | 0.19% |
| Divi's Laboratories Ltd | 76.08 | 12.28 | 0.48% |
| Syngene International Ltd | 52.26 | 6.09 | 0.19% |
| Aarti Pharmalabs Ltd | 26.50 | 4.11 | 0.31% |
VIMTALABS Stock Price Comparison
Compare VIMTALABS with any stock or ETFCompare VIMTALABS with any stock or ETF
VIMTALABS
VIMTALABS Shareholdings
VIMTALABS Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
VIMTALABS Institutional Holdings Trend
Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has decreased by 1.65%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
VIMTALABS Shareholding Pattern
VIMTALABS Shareholding History
Foreign Institutions
Mutual Funds Invested in VIMTALABS
A list of mutual funds holding the stock, ranked on the basis of Market-cap held which is calculated as the value of stock held in the portfolio divided by its market cap
Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 1 Mutual Funds holding Vimta Labs Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0005% | Percentage of the fund’s portfolio invested in the stock 0.06% | Change in the portfolio weight of the stock over the last 3 months 0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 92/109 (-6) |
Compare 3-month MF holding change on Screener
smallcases containing VIMTALABS stock
Looks like this stock is not in any smallcase yet.
VIMTALABS Events
VIMTALABS Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
VIMTALABS has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.19%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.92 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
VIMTALABS Upcoming Dividends
No upcoming dividends are available
VIMTALABS Past Dividends
Cash Dividend
Ex DateEx DateJul 11, 2024
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jul 11, 2024
Cash Dividend
Ex DateEx DateJun 21, 2023
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jun 21, 2023
Cash Dividend
Ex DateEx DateJun 16, 2022
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jun 16, 2022
Cash Dividend
Ex DateEx DateJun 25, 2021
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jun 25, 2021
Cash Dividend
Ex DateEx DateJul 18, 2019
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jul 18, 2019
VIMTALABS Stock News & Opinions
Articles & Videos
Corporate
Vimta Labs to hold AGM
Vimta Labs announced that the 35th Annual General Meeting(AGM) of the company will be held on 6 June 2025.Powered by Capital Market - Live
11 hours agoCapital Market - Live
Spotlight
Vimta Labs rises after strong Q4 performance; board OKs 1:1 bonus share issue
EBITDA improved by 31.9% to Rs 34.68 crore in Q4 FY25 from Rs 26.30 crore in Q4 FY24. EBITDA margin was 36.1% in Q4 FY25 as against 36.0% in Q4 FY24. Profit before tax in Q4 FY25 stood at Rs 25.03 crore, up by 39.5% from Rs 17.94 crore recorded in Q4 FY24. Tax outgo for the fourth quarter was Rs 6.71 crore as against Rs 3.98 crore in the same period last year. Vimta Labs has reported 36.8% rise in net profit to Rs 66.75 crore on a 19.1% increase in total income to Rs 348.22 crore in FY25 as compared with FY24. Total debt as of 31 March 2025 stood at Rs. 8.5 crore. Cash and cash equivalents, including bank balance, stood at Rs 32.9 crore as of 31 March 2025. The board of Vimta Labs has granted its approval for increasing the company's borrowing powers up to Rs 300 crore, subject to approval of shareholders at the ensuing annual general meeting. The company's board has approved a dividend of Rs 2 per equity share for the financial year 2024-25. The board has also recommended the issue of bonus shares in the ratio of 1:1, subject to the approval of shareholders in the ensuing AGM. Vimta Labs has announced its strategic expansion into Biologics Contract Research and Development services. This foray marks a significant milestone in our growth journey, reinforcing our commitment to serve the evolving needs of the biopharmaceutical industry. The new service line will focus on Novel Biologic Entities (NBEs), biosimilars, and peptide-based therapeutics using both microbial and mammalian platforms. Capabilities will include end-to-end development ' from clone and process development to drug product development and biosimilarity assessment. Development lab is being set up, with requisite manpower by Q3 of FY26, and revenues are expected to commence from FY27,' the company stated. Harita Vasireddi, managing director, Vimta Labs, said: We are pleased to report strong earnings and good growth this year, driven by growth in pharmaceutical services. Our pharma business benefited from increased traction in clinical and analytical services, supported by capacity expansion and deeper client engagements. We are excited to announce our entry into Biologics Contract R&D services, a strategic move that aligns with the future of healthcare and enhances our capabilities across the biopharma value chain. This initiative will enable Vimta to offer end-to-end support for biologics development, reinforcing our position as a trusted partner in high-quality, science-driven innovation. Vimta Labs is a leading contract research and testing organization, providing food, agri, bio/pharmaceutical, medical device, speciality chemical, and electronics companies an integrated scientific, technical, and regulatory expertise to support all stages of product development and manufacturing process. Vimta also provides environmental assessments and testing services. Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Earnings
Vimta Labs standalone net profit rises 48.34% in the March 2025 quarter
Net profit of Vimta Labs rose 48.34% to Rs 18.32 crore in the quarter ended March 2025 as against Rs 12.35 crore during the previous quarter ended March 2024. Sales rose 29.85% to Rs 94.44 crore in the quarter ended March 2025 as against Rs 72.73 crore during the previous quarter ended March 2024. For the full year,net profit rose 64.20% to Rs 67.34 crore in the year ended March 2025 as against Rs 41.01 crore during the previous year ended March 2024. Sales rose 19.19% to Rs 343.98 crore in the year ended March 2025 as against Rs 288.60 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales94.4472.73 30 343.98288.60 19 OPM %34.9935.64 -35.4532.58 - PBDT34.2425.77 33 124.2995.64 30 PBT25.0317.93 40 89.0062.50 42 NP18.3212.35 48 67.3441.01 64 Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Board of Vimta Labs approves increase in borrowing powers up to Rs 300 cr
The board of Vimta Labs at its meeting held on 28 April 2025 has approved increase of Borrowing Powers up to Rs. 300 crore subject to approval of shareholders at the ensuing Annual General Meeting. Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Board of Vimta Labs approves foray into Biologics Contract Research and Development
The board of Vimta Labs at its meeting held on 28 April 2025 has approved the company's foray into Biologics Contract Research and Development with an investment of Rs 50 crore. The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides. Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Board of Vimta Labs approves bonus issue of 1:1
The board of Vimta Labs at its meeting held on 28 April 2025 has approved issue of bonus equity shares in ratio of 1:1. Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Board of Vimta Labs recommends Final Dividend
Vimta Labs announced that the Board of Directors of the Company at its meeting held on 28 April 2025, has recommended a Final dividend of Rs.2 per share (i.e.100%), subject to the approval of the shareholders.Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Vimta Labs declare Quarterly Result
Vimta Labs will hold a meeting of the Board of Directors of the Company on 28 April 2025.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Vimta Labs allots 11,726 equity shares under ESOP
Vimta Labs has allotted 11,726 equity shares under ESOP on 20 March 2025. With this allotment, the paid up equity share capital has increased to Rs. 4,44,69,024 consisting of 2,22,34,512 equity shares having a face value of Rs. 2 each. Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Vimta Labs consolidated net profit rises 112.24% in the December 2024 quarter
Net profit of Vimta Labs rose 112.24% to Rs 21.50 crore in the quarter ended December 2024 as against Rs 10.13 crore during the previous quarter ended December 2023. Sales rose 20.57% to Rs 89.92 crore in the quarter ended December 2024 as against Rs 74.58 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales89.9274.58 21 OPM %36.7932.05 - PBDT33.7224.07 40 PBT23.9215.64 53 NP21.5010.13 112 Powered by Capital Market - Live
3 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 8.48%, vs industry avg of 4.6%
Over the last 5 years, market share increased from 1.71% to 1.82%
Over the last 5 years, net income has grown at a yearly rate of 10.13%, vs industry avg of 6%